Regulatory Reckoning: DOJ Targets Telehealth Fraud, CA Scrutinizes CPOM, FDA Clarifies Peptide Status

2026-07-29

Recent regulatory actions signal a profound shift in healthcare compliance, with the DOJ aggressively prosecuting telehealth fraud and California intensifying Corporate Practice of Medicine enforcement. Meanwhile, the FDA clarifies the complex legal status of compounded peptides. Understanding these critical developments is essential for telehealth operators, medspas, and clinical practices navigating a rapidly evolving landscape.

The healthcare regulatory landscape is in constant motion, a dynamic environment shaped by aggressive enforcement, evolving state laws, and agency guidance. For telehealth operators, medspa owners, and traditional clinical practices expanding nationally, staying abreast of these shifts is not merely advisable—it is an existential imperative. Recent months have underscored a significant escalation in regulatory scrutiny, particularly targeting fraudulent telemedicine schemes, the intricate nuances of the Corporate Practice of Medicine, and the highly complex domain of compounded therapies. This roundup dissects the latest developments, offering critical insights to fortify your compliance framework.

> For more on this topic, see our analysis: [Navigating the Enforcement Tide: Telehealth Fraud, Peptide Scrutiny, and CPOM Crackdowns](/blog/enforcement-telehealth-peptide-cpom-crackdowns).

Heightened Federal Scrutiny on Telehealth Fraud: A Clear Warning

The Department of Justice (DOJ) has unmistakably signaled its intent to aggressively pursue healthcare fraud, with a particular focus on the burgeoning telehealth sector. The scale of recent enforcement actions serves as a stark reminder of the risks associated with non-compliant remote care models.

> For more on this topic, see our analysis: [Navigating the Enforcement Tide: Telehealth Fraud, Peptide Scrutiny, and CPOM Crackdowns](/blog/enforcement-telehealth-peptide-cpom-crackdowns).

The National Health Care Fraud Takedown and its Aftermath

In a sweeping action, the DOJ's National Health Care Fraud Takedown charged 455 defendants across the country, alleging $1.2 billion in telemedicine fraud. This operation, one of the largest in DOJ history, highlights a critical enforcement trend: the targeting of schemes that exploit the reach of telehealth for illicit gains. These schemes frequently involve:

Fraudulent Orders for Unnecessary Equipment: The takedown emphasized cases where patient data was purchased, and practitioner signatures were obtained for medical equipment or durable medical equipment (DME) that was not medically necessary. A recent conviction in Florida illustrates this perfectly, involving a medical supply company owner and a chiropractor in a $30 million scheme built on fraudulent orders for unneeded equipment. This case underscores the federal government's commitment to prosecuting those who subvert the principle of medical necessity for profit, particularly within federally funded programs like Medicare, TRICARE, and CHAMPVA.
Lack of Bona Fide Patient-Practitioner Relationships: The core of many fraudulent telemedicine schemes lies in the absence of a legitimate, clinical relationship between the patient and the prescribing practitioner. This often involves practitioners rubber-stamping orders without proper evaluation, relying instead on high-pressure telemarketing or patient brokers.

The Coeur d’Alene Physician Sentencing: A Personal Cost

Further emphasizing the severe consequences for individual practitioners, Dr. David Antonio Becerril, a physician from Coeur d’Alene, Idaho, was sentenced in September 2025 to 40 months imprisonment and ordered to pay $1.25 million in restitution. His conviction on 16 felony counts, including healthcare and wire fraud, stemmed from his role in a nationwide telemarketing conspiracy that defrauded Medicare through fraudulent telemedicine practices. Dr. Becerril's case is a poignant illustration that individual accountability for facilitating or participating in fraudulent billing schemes will be aggressively pursued, leading to significant personal and professional ruin.

Actionable Insight: For all healthcare businesses, particularly telehealth providers and practices expanding into remote care, these actions are a clarion call. Robust compliance programs must be in place to ensure: (1) all services are medically necessary; (2) legitimate patient-provider relationships are established and documented; and (3) all billing is accurate and compliant with federal and state regulations. Any business model relying on generating orders or prescriptions without a direct, legitimate clinical evaluation is operating at extreme risk.

California Intensifies Corporate Practice of Medicine Enforcement

The regulatory landscape for healthcare businesses operating under a Professional Corporation/Management Services Organization (PC/MSO) model has seen a dramatic shift, particularly in California. The state's Attorney General is now actively enforcing Corporate Practice of Medicine (CPOM) restrictions with renewed vigor, moving beyond mere legalistic interpretations to scrutinize the actual control exerted by MSOs or investors over medical practices.

The "Actual Control" Doctrine in Action

California's heightened scrutiny is not a theoretical exercise. A recent $2.3 million settlement with a dental services organization exemplifies the state's aggressive stance. This enforcement action targeted contractual arrangements that granted the MSO de facto control over clinical decisions, practice ownership, and even public communications. Key areas of focus for the Attorney General include:

Clinical Decision-Making: MSOs must not dictate or influence clinical protocols, treatment plans, or provider hiring/firing decisions. These remain the sole purview of the licensed professional corporation.
Ownership and Management: While MSOs can provide administrative support, they cannot indirectly own or manage the professional practice itself. Agreements must explicitly preserve the professional corporation's autonomy.
Public Communications and Advertising: Any public-facing statements, marketing materials, or advertising must accurately represent the professional practice as physician-owned and controlled, avoiding any implication of MSO ownership or clinical authority.
Compensation Methodologies: MSO compensation structures must not incentivize medically unnecessary services or create a financial incentive for the MSO to influence clinical decisions.

Actionable Insight: For telehealth brands, medspas, dental practices, chiropractic offices, and all healthcare entities utilizing a PC/MSO model in California, this development is critical. Agreements must be meticulously reviewed to ensure licensed professionals retain unequivocal authority over all clinical decisions, provider relationships, and core practice operations. The focus is no longer just on the letter of the law, but on the practical reality of control. Failure to adapt could lead to significant financial penalties and operational disruptions, including potential orders to restructure or cease operations.

The Complexities of Drug Compounding and Supply Chain Integrity

Beyond direct patient care models, regulatory vigilance extends to the pharmaceutical supply chain and the growing area of compounded medications, particularly peptides. Recent FDA actions and advisory committee discussions highlight both ongoing enforcement and critical future considerations for providers.

FDA Debarment: A Reminder on Supply Chain Due Diligence

The Food and Drug Administration (FDA) plays a crucial role in safeguarding the integrity of the U.S. drug supply. A recent 5-year debarment order against Francis Esteban Matos for felony drug importation violations underscores this vigilance. While many practices do not directly import drugs, they rely on a complex ecosystem of suppliers and distributors. Engaging, even indirectly, with individuals or entities involved in unlawful importation poses significant risks, including the introduction of unapproved, misbranded, or adulterated products into patient care. Such failures can lead to severe patient safety risks and catastrophic legal consequences for the practice.

Actionable Insight: All healthcare businesses must exercise robust due diligence when selecting suppliers, distributors, and partners for drugs, medical devices, and related substances. Verify their licenses, compliance history, and sourcing practices to ensure adherence to federal law. Even when managed by a third party, compliance with federal importation laws remains the ultimate responsibility of the healthcare entity.

Peptides and Compounding: Navigating the Legal Labyrinth Post-Advisory Vote

The burgeoning interest in peptides like BPC-157, KPV, and TB-500 for various therapeutic applications has led to significant regulatory discussion. The FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026, to evaluate several peptides for potential inclusion on the Section 503A bulk drug substances list. This vote is pivotal, as inclusion on this list dictates which substances can be legally compounded by 503A pharmacies for patient-specific prescriptions.

Advisory, Not Legalization: The PCAC voted to recommend adding six of the seven peptides discussed—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—to the 503A list, while rejecting Emideltide (DSIP). However, it is crucial to understand that this vote is advisory and non-binding. These peptides are not yet FDA-approved and are not yet legal to compound or sell for human use.
Future Rulemaking: Final legality requires formal FDA rulemaking, a process typically expected no earlier than 2027. Until then, the regulatory status of these substances remains unchanged.
"Research Use Only" Risks: Operators and providers fielding questions about these peptides must be unequivocally clear: "research use only" sales for human use are unlawful and are actively being prosecuted criminally. Marketing or dispensing these peptides now, or sourcing them from unvetted "research-use-only" vendors, carries significant unapproved-drug and misbranding risks.

Actionable Insight: For telehealth brands, medspas, GLP-1 clinics, and longevity practices, the July 2026 PCAC votes signal a potential future pathway, but it is not yet open. The compliant approach involves preparing your infrastructure: securing licensed prescribers, ensuring valid patient-specific prescriptions, and vetting 503A pharmacy relationships. This proactive preparation allows for rapid, compliant operation *if and when* the FDA finalizes a rule, rather than risking enforcement by getting ahead of the regulatory curve. Accurate patient education regarding the current legal status is paramount to avoid misrepresentation and non-compliance.

State-Specific Nuances: The Kentucky Cannabis Example

While federal enforcement and broad state-level actions capture headlines, granular state-specific regulations often dictate the practical realities of care delivery. The evolving landscape of medical cannabis provides a clear example of how state laws can impose specific, often unexpected, limitations on telehealth models.

Initial In-Person Requirements for Medical Cannabis Certification

Kentucky's Medical Cannabis Program outlines specific requirements for physicians and advanced practice registered nurses (APRNs) to provide written certifications for medical cannabis. Critically, it mandates an initial in-person patient examination to establish a bona fide practitioner-patient relationship. While subsequent certifications and relationship maintenance *can* occur via telehealth, the initial in-person visit is non-negotiable.

Actionable Insight: For telehealth providers operating or considering operations in Kentucky, this guidance is a vital example of how state-specific mandates can supersede general telehealth allowances. A purely virtual model for initial patient engagement in this context is non-compliant. Telehealth companies must either implement a hybrid care model, facilitate in-person evaluations through partnerships, or ensure their practitioners are fully aware of and adhere to this specific state mandate. Diligent documentation of the in-person visit, patient review, counseling, and consent requirements, along with proper state registration, is essential to avoid regulatory scrutiny.

What This Means For Your Practice: Navigating Forward

The confluence of these regulatory and enforcement actions paints a clear picture: the era of lax compliance, especially in rapidly innovating sectors like telehealth and wellness, is decisively over. Healthcare businesses must adapt to an environment characterized by heightened scrutiny and aggressive enforcement.

1. Reinforce Your Compliance Program: This is not a static document but a living framework. Regularly review and update policies and procedures to reflect new regulations, enforcement trends, and internal operational changes. Ensure staff are trained and understand their roles in maintaining compliance. 2. Prioritize Medical Necessity and Documentation: Every service, prescription, and order must be medically necessary and thoroughly documented. This is the bedrock against fraud allegations. Scrutinize any business model that incentivizes volume over clinical appropriateness. 3. Audit PC/MSO Structures: For practices utilizing MSOs, particularly in states like California, conduct a comprehensive legal review of all contractual agreements and operational practices to ensure that licensed professionals retain ultimate clinical control and decision-making authority. 4. Vet Your Supply Chain and Partners: Conduct rigorous due diligence on all suppliers, compounding pharmacies, and third-party vendors to ensure they are compliant with federal and state regulations, particularly concerning drug sourcing and compounding. 5. Stay Informed on Emerging Therapies: For novel treatments like peptides, understand that advisory committee votes are not final legalizations. Build compliant infrastructure ahead of time, but do not operate outside established legal frameworks. Accurate patient education is paramount. 6. Seek Expert Legal Counsel: The complexity and rapid evolution of healthcare law necessitate ongoing consultation with legal experts specializing in healthcare compliance. Proactive legal guidance is an investment that safeguards your practice from significant liabilities.

TrueEval stands as your definitive partner in navigating this intricate landscape. By providing unparalleled insights and robust compliance infrastructure, we empower healthcare businesses to innovate confidently, ensuring adherence to the highest standards of regulatory integrity and patient safety. The future of healthcare is bright for those who build it on a foundation of unyielding compliance.